Shilpa Medicare arm signs licensing pact with Steincares to expand in Latin AmericaShilpa Medicare arm signs licensing pact with Steincares to expand in Latin America

Introduction

Leading biopharmaceutical company signs licensing agreement with a Latin American healthcare firm to commercialize a biosimilar, handling product development and long-term manufacturing for the region.

Also Read: DEE Development hits 20% upper circuit on securing ₹173 Cr global contracts across India and Thailand

Share price movement of Shilpa Medicare

On February 24, 2026, Shilpa Medicare Ltd opened at ₹318.50, down 2.40% from its previous close of ₹327.30. The stock reached a high of ₹326.75, a 0.29% gain, and a low of ₹318.50. By 3:12 PM, it traded at ₹319.45, a 2.40% decrease, with a market cap of ₹6,247.86 crore.

Shilpa Biologicals Partners with SteinCares

Shilpa Biologicals Pvt. Ltd., a subsidiary of Shilpa Medicare Ltd., has signed a licensing agreement with SteinCares to commercialize a biosimilar across Latin America.

Under the agreement, SteinCares will have exclusive rights to register, market, and distribute the biosimilar, while Shilpa Biologicals will handle product development and long-term commercial manufacturing.

The partnership combines Shilpa Biologicals’ biologics expertise with SteinCares’ regional commercialization platform. It marks Shilpa Biologicals’ entry into Latin America and strengthens SteinCares’ biosimilar portfolio.

Stock performance of Shilpa Medicare for period of 1 week, 6 months, and 1 year

Shilpa Medicare Ltd delivered a 2.05% decline over the past week and fell 22.5% in the past 6 months. The stock gained 0.41% over the past 1 year.

Also Read: Valiant Communications successfully tests hardware-based Kill Switch for mission-critical networks

Shareholding pattern of Shilpa Medicare

Particulars	Dec 2025	Sep 2025	Jun 2025
Promoter	40.10%	44.20%	44.20%
FII	11.00%	10.90%	11.20%
DII	8.30%	7.70%	7.50%
Public	40.60%	37.20%	37.10%

About Shilpa Medicare

Shilpa Medicare Ltd (NSE: SHILPAMED), founded in 1987, manufactures APIs, intermediates, and formulations, including injectables and oral solids, and offers contract research and manufacturing services.

Stay Ahead with the Latest Stock Market Updates – Click Here

Disclaimer: The above article is written for educational purposes, and the companies’ data mentioned in the article may change with respect to time. The securities quoted are exemplary and are not recommendatory.

FAQs